Paulo Gustavo Kotze, Takayuki Yamamoto, Silvio Danese, Yasuo Suzuki, Fabio Vieira Teixeira, Idblan Carvalho de Albuquerque, Rogerio Saad-Hossne, Ivan Folchini de Barcelos, Rodolff Nunes da Silva, Lorete Maria da Silva Kotze, Márcia Olandoski, Matteo Sacchi, Akihiro Yamada, Ken Takeuchi, Antonino Spinelli
BACKGROUND AND AIMS: Both adalimumab [ADA] and infliximab [IFX] seem to be effective in the prevention of early postoperative endoscopic recurrence [EPER] after ileocaecal resection in Crohn's disease [CD] patients. There is lack of data with direct comparison between the two agents in the postoperative scenario. The aim of this study was to compare the rates of EPER in patients treated with ADA and IFX after ileocaecal resection for CD. METHODS: This was a multicentre retrospective analysis of EPER rates in CD patients after ileocaecal resections, from seven referral centres in three countries...
July 2015: Journal of Crohn's & Colitis